Participants
allergic, fever, cholangitis, sepsis-related organ damage, acholic, end-stage liver failure, liver disease, jaundice, known immunodeficiency, infection, allergies
HEMOLYTIC JAUNDICE, CHOLANGITIS, VIRAL INFECTION, LIVER DISEASE, INFECTION, ALLERGIES, COMPLICATIONS
Patients with an episode of cholangitis was defined as the presence of unexplained fever (≥38°C) combined with at least one of the following findings: recurrent jaundice or acholic stools; direct bilirubin (DBIL) greater than or equal to 20 µmol/l; white blood cell count (WBC) greater than or equal to 10×10Inclusion criteria were: patients diagnosed with type III BA who underwent KPE. The diagnosis of type III BA is based on intraoperative cholangiography in combination with histologic features of liver biopsies; suffering from an episode of cholangitis; not receiving other antibiotics or probiotics prior to enrollment; informed consent and willingness of their parents to cooperate with treatment and follow-up; not allergic to the medication. In addition, if the parents withdrew consent for any reason, or if the patient developed serious complications, the study would be discontinued and the subsequent alternative clinical management would be offered.We excluded participants with known immunodeficiency, known viral infection, an identified source of infection other than cholangitis, end-stage liver failure, hemolytic jaundice, known allergies, or other contraindications to the use of IVIG, cefoperazone sodium tazobactam sodium (CSTS) and MEPM, a history of cholangitis unresponsive to CSTS, unstable conditions and sepsis-related organ damage, other liver disease or severe comorbidities requiring surgical interventionIndications for discharge from the hospital were: fever-free for 72 h and normal levels of WBC (<10×10